These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28665681)

  • 1. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Barry PM; Lowenthal P; True L; Henry L; Schack G; Wendorf K; Flood J; Shah N
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1488-1489. PubMed ID: 28665681
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Varaine F; Guglielmetti L; Mitnick CD
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1490-1491. PubMed ID: 28715258
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    van Leth F; Günther G; Hoffmann H; Lange C;
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1489-1490. PubMed ID: 28715229
    [No Abstract]   [Full Text] [Related]  

  • 4. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Munoz-Torrico M; Salazar MA; Millán MJM; Martínez Orozco JA; Narvaez Diaz LA; Segura Del Pilar M; Visca D; D'Ambrosio L; Centis R; Migliori GB
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567721
    [No Abstract]   [Full Text] [Related]  

  • 5. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
    Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F;
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis.
    Sotgiu G; Migliori GB
    Lancet Respir Med; 2017 Mar; 5(3):159-161. PubMed ID: 27989590
    [No Abstract]   [Full Text] [Related]  

  • 7. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Varaine F; Guglielmetti L; Huerga H; Bonnet M; Kiria N; Sitienei JK; Rich M; Mitnick CD
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1028-1029. PubMed ID: 27739887
    [No Abstract]   [Full Text] [Related]  

  • 8. Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope.
    Prasad R; Gupta N; Banka A
    Indian J Med Res; 2017 Sep; 146(3):301-303. PubMed ID: 29355135
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Chesov D; Ciobanu N; Lange C; Heyckendorf J; Crudu V
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025881
    [No Abstract]   [Full Text] [Related]  

  • 10. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 11. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
    Achar J; Berry C; Herboczek K; Parpieva N; Tillyashaykhov MN; Tigay ZN; Khamraev A; Velivela K; Seddon JA; du Cros P
    Emerg Infect Dis; 2015 Nov; 21(11):2105-6. PubMed ID: 26488556
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Arakaki Sanchez D; Dockhorn F; Centis R; Migliori GB
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28404651
    [No Abstract]   [Full Text] [Related]  

  • 14. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistant Mycobacterium tuberculosis in California, 1991 to 1992.
    Koo D; Royce S; Rutherford GW
    West J Med; 1995 Nov; 163(5):441-5. PubMed ID: 8533406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    van der Werf MJ; Ködmön C; Catchpole M
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572128
    [No Abstract]   [Full Text] [Related]  

  • 17. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Heldal E; Van Deun A; Chiang CY; Rieder HL
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572127
    [No Abstract]   [Full Text] [Related]  

  • 18. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.
    Kendall EA; Fojo AT; Dowdy DW
    Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the best regimen to treat isoniazid-resistant tuberculosis.
    Migliori GB; Tiberi S; Sotgiu G
    Lancet Respir Med; 2018 Apr; 6(4):233-235. PubMed ID: 29595499
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis.
    Sougakoff W
    Clin Microbiol Infect; 2011 Jun; 17(6):800-5. PubMed ID: 21682800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.